Stay updated on Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial page.

Latest updates to the Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedA consolidated 'Locations' section was added listing California, Indiana, Kentucky, Nebraska, New Jersey, and Virginia, with the former separate state location entries removed; the revision tag was updated from v3.3.2 to v3.3.3.SummaryDifference0.7%

- Check23 days agoNo Change Detected
- Check44 days agoChange DetectedAdded `Revision: v3.3.2` and removed `Revision: v3.2.0`.SummaryDifference0.1%

- Check52 days agoChange DetectedNotice about potential delays due to a lapse in government funding and related operating status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check73 days agoChange DetectedNo significant changes to the study page were detected; core details such as the title, phase, eligibility criteria, and locations remain unchanged.SummaryDifference0.4%

- Check94 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference3%

- Check102 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.1%

Stay in the know with updates to Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial page.